HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

The downregulation of Pleckstrin Homology-Like Domain family A member 1 (PHLDA1) expression mediates resistance to targeted therapies in receptor tyrosine kinase-driven cancers. The restoration and maintenance of PHLDA1 levels in cancer cells thus constitutes a potential strategy to circumvent resistance to inhibitors of receptor tyrosine kinases. Through a pharmacological approach, we identify the inhibition of MAPK signalling as a crucial step in PHLDA1 downregulation. Further ChIP-qPCR analysis revealed that MEK1/2 inhibition produces significant epigenetic changes at the PHLDA1 locus, specifically a decrease in the activatory marks H3Kme3 and H3K27ac. In line with this, we show that treatment with the clinically relevant class I histone deacetylase (HDAC) inhibitor 4SC-202 restores PHLDA1 expression in lapatinib-resistant human epidermal growth factor receptor-2 (HER2)+ breast cancer cells. Critically, we show that when given in combination, 4SC-202 and lapatinib exert synergistic effects on 2D cell proliferation and colony formation capacity. We therefore propose that co-treatment with 4SC-202 may prolong the clinical efficacy of lapatinib in HER2+ breast cancer patients.

References Powered by Scopus

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

75634Citations
N/AReaders
Get full text

Cancer drug resistance: An evolving paradigm

3703Citations
N/AReaders
Get full text

THE TOXICITY OF POISONS APPLIED JOINTLY

1792Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A narrative review of epigenetic marker in H3K27ac and its emerging potential as a therapeutic target in cancer

0Citations
N/AReaders
Get full text

Expanding on roles of pleckstrin homology-like domain family A member 1 protein

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Clayton, N. S., Carter, E. P., Fearon, A. E., Heward, J. A., Rodríguez Fernández, L., Boughetane, L., … Grose, R. P. (2023). HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction. International Journal of Molecular Sciences, 24(7). https://doi.org/10.3390/ijms24076228

Readers over time

‘23‘2401234

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 1

50%

Biochemistry, Genetics and Molecular Bi... 1

50%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0